Alivus Life Sciences Ltd

- The company currently has five ongoing CDMO projects. - Projects 4 and 5 together have an expected peak revenue potential of around $12 million, likely reaching this by the second half of FY'27. - The earlier three CDMO projects generate a run rate of about Rs. 140 crores annually. - Alivus is in advanced discussions for two additional CDMO projects expected to be locked by Q1 FY'27. - Anticipated future CDMO contract sizes remain in the $4-6 million range, consistent with current deal sizes. - Overall, the CDMO order book is growing steadily with new projects expected to contribute incrementally from FY'28 onward.

- There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript. - The company emphasizes that it remains a net debt-free company with strong free cash flow generation (Rs. 221 crores in 9 months FY’26). - Management indicates a cautious approach to inorganic growth and investments, stating they are open to opportunities but will deploy capital judiciously. - Organic growth and capacity expansions are mainly funded through operational cash flows and CAPEX plans. - CAPEX for FY’26 is guided at Rs. 450 crores, partially deferred to FY’27, indicating reliance on internal funds rather than external fundraising. - No mention of equity issuance or debt raising plans for future expansions or operations.

- Capacity expansion from 1,400 KL to 2,100 KL reactor capacity planned over the next year, including brownfield expansions at Dahej and Ankleshwar, operational from Q2 FY'27, providing runway for at least two years for regulated markets. - Solapur plant delayed by approximately three months; expected to start operations by July 2026, initially focused on ROW (Rest of World) markets with gradual shift to regulated markets expected by late FY'28. - Solapur capacity slightly recalibrated from initially planned 600 KL to around 450-500 KL in phase 1, based on product mapping to avoid under-utilization. - 400 KL capacity allocated specifically for backward integration to secure supply and margin protection for high-value molecules. - New R&D facility inauguration planned to enhance R&D capabilities focusing on flow chemistry, green chemistry, and particle engineering for new molecule development. - Management is open to inorganic investments but will pursue only well-defined, value-accretive opportunities cautiously.

- High single-digit revenue growth is expected for FY'26, with 5% price erosion factored in and 15-17% volume growth anticipated. - From FY'28-'29, the full capacity of the Solapur plant going live is expected to drive double-digit growth. - Mature molecules show stable volumes with 2-3% growth, while newer launches and upcoming patent expiries offer significant volume expansion opportunities. - The CDMO business, despite smaller deal sizes (around $6 million per project), is scaling with steady contributions from current projects and potential new contracts expected in FY'27. - Continued focus on high-quality, high-margin businesses aims to generate steady cash flow supporting organic and selective inorganic growth. - Capacity expansions at Dahej, Ankleshwar, and Solapur ensure no capacity constraints for growth over the next 2-3 years.

- The company expects high single-digit revenue growth for FY'26, driven by strong expansion in the non-GPL segment and ramp-up of CDMO projects. - EBITDA margins are forecasted to be in the 30%-32% range going forward, an improvement from earlier guidance of 28%-30%, due to operational efficiencies and new product launches. - Non-GPL business is growing in the mid-teens percentage range, contributing around 70%-75% of overall business. - Volume growth is anticipated at approximately 15%-17% with an expected 5% price erosion factored in. - CDMO segment has shown strong recovery with 100% QoQ revenue growth in Q3 and is expected to contribute positively to margins and profits. - Double-digit growth is anticipated from FY'28-'29 onwards, particularly after full capacity utilization of the Solapur plant. - The company remains focused on maintaining a high-quality, cash-generative business rather than pursuing low-margin volume growth.